Mo1560 CANNABIS USE IS ASSOCIATED WITH REDUCED 30-DAY READMISSION AMONG HOSPITALIZED PATIENTS WITH IRRITABLE BOWEL SYNDROME: A NATIONWIDE ANALYSIS

Choi, Catherine; Abougergi, Marwan S.; Peluso, Heather; Patel, Preet; Pyrsopoulos, Nikolaos

doi:10.1016/s0016-5085(20)32925-5

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, Cannabis use appeared to correlate with shorter hospital stays leading to lower total hospitalization charges. Cannabis use was also associated with a slightly higher survival rate compared with non-users (45).…”

Section: Inflammatory Bowel Disease and Irritable Bowel Syndromementioning

confidence: 90%

See 1 more Smart Citation

Cannabis and the Gastrointestinal Tract

Cohen

Neuman

2020

J Pharm Pharm Sci

View full text Add to dashboard Cite

Cannabis has been used for its medicinal purposes since ancient times. Its consumption leads to the activation of Cannabis receptors CB1 and CB2 that, through specific mechanisms can lead to modulation and progression of inflammation or repair. The novel findings are linked to the medical use of Cannabis in gastrointestinal (GI) system. PURPOSE: The objective of the present paper is to elucidate the role of Cannabis consumption in GI system. An additional aim is to review the information on the function of Cannabis in non-alcoholic fatty liver disease (NAFLD). METHODS AND RESULTS: This review summarizes the recent findings on the role of cannabinoid receptors, their synthetic or natural ligands, as well as their metabolizing enzymes in normal GI function and its disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and possible adverse events. The synergism or antagonism between Cannabis’ active ingredients and the “entourage” plays a role in the efficacy of various strains. Some elements of Cannabis may alter disease severity as over-activation of Cannabis receptors CB1 and CB2 can lead to changes of the commensal gut flora. The endocannabinoid system (ECS) contributes to gut homeostasis. The ability of ECS to modulate inflammatory responses demonstrates the capacity of ECS to preserve gastrointestinal (GI) function. Alterations of the ECS may predispose patients to pathologic disorders, including IBD. Clinical studies in IBD demonstrate that subjects benefit from Cannabis consumption as seen through a reduction of the IBD-inflammation, as well as through a decreased need for other medication. NAFLD is characterized by fat accumulation in the liver. The occurrence of inflammation in NAFLD leads to non-alcoholic-steatohepatitis (NASH). The use of Cannabis might reduce liver inflammation. CONCLUSIONS: With limited evidence of efficacy and safety of Cannabis in IBD, IBS, and NAFLD, randomized controlled studies are required to examine its therapeutic efficacy. Moreover, since long term use of the plant leads to drug use disorders the patients should be followed continuously.

show abstract

Section: Inflammatory Bowel Disease and Irritable Bowel Syndromementioning

confidence: 90%

“…An additional study by Coi et al (45) summarizes an analysis of the Agency for Healthcare Research and Quality's 2016 Nationwide Re-admissions Database. The team identified 6,798 adult patients with IBS of whom 357 were Cannabis users who participated at the study.…”

Section: Inflammatory Bowel Disease and Irritable Bowel Syndromementioning

confidence: 99%

Cannabis and the Gastrointestinal Tract

Cohen

Neuman

2020

J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

Mo1560 CANNABIS USE IS ASSOCIATED WITH REDUCED 30-DAY READMISSION AMONG HOSPITALIZED PATIENTS WITH IRRITABLE BOWEL SYNDROME: A NATIONWIDE ANALYSIS

Cited by 1 publication

References 0 publications

Cannabis and the Gastrointestinal Tract

Cannabis and the Gastrointestinal Tract

Contact Info

Product

Resources

About